Results 21 to 30 of about 1,251,690 (298)

Costs of orphan medicinal products: longitudinal analysis of expenditure in Wales

Orphanet Journal of Rare Diseases, 2023
Background The Orphan Regulation ((EC) No 141/2000) has successfully redirected private and public investment towards previously neglected areas through incentives, regulatory obligations and rewards.
Yankier Pijeira Perez, Eifiona Wood, Dyfrig A Hughes   +2 more
doaj   +1 more source

Out-of-pocket expenditure for administration of benzathine penicillin G injections for secondary prophylaxis in patients with rheumatic heart disease: A registry-based data from a tertiary care center in Northern India

Indian Heart Journal, 2021
Background: Costs can be a major barrier to medication adherence in low and middle-income countries and are an important target for policy-level interventions.
Balaji Arvind, Anita Saxena, Dhruv S. Kazi, Ann F. Bolger   +3 more
doaj   +1 more source

Evaluation of the Direct Costs of Managing Adverse Drug Events in all Ages and of Avoidable Adverse Drug Events in Older Adults in Japan

Frontiers in Pharmacology, 2021
In Japan, medical costs are increasing annually, and the increase in national medical costs, particularly in the direct cost of managing adverse drug events, is high. An in-depth understanding of these costs is important for their reduction.
Hayato Katsuno, Hayato Katsuno, Tomoya Tachi, Tomoya Tachi, Takuya Matsuyama, Mayuko Sugioka, Satoshi Aoyama, Tomohiro Osawa, Yoshihiro Noguchi, Masahiro Yasuda, Chitoshi Goto, Takashi Mizui, Hitomi Teramachi, Hitomi Teramachi   +13 more
doaj   +1 more source

How Risky Is That Risk Sharing Agreement? Mean-Variance Tradeoffs and Unintended Consequences of Six Common Risk Sharing Agreements

MDM Policy & Practice, 2021
Background. Pharmaceutical risk sharing agreements (RSAs) are commonly used to manage uncertainties in costs and/or clinical benefits when new drugs are added to a formulary.
Gregory S. Zaric
doaj   +1 more source

New Anticancer Drugs: Reliably Assessing “Value” While Addressing High Prices

Current Oncology
Countries face challenges in paying for new drugs. High prices are driven in part by exploding drug development costs, which, in turn, are driven by essential but excessive regulation.
David J. Stewart, John-Peter Bradford, Sandeep Sehdev, Tim Ramsay, Vishal Navani, Nigel S. B. Rawson, Di Maria Jiang, Joanna Gotfrit, Paul Wheatley-Price, Geoffrey Liu, Alan Kaplan, Silvana Spadafora, Shaun G. Goodman, Rebecca A. C. Auer, Gerald Batist   +14 more
doaj   +1 more source

Therapeutic Drug Monitoring by Pharmacists: Does It Reduce Costs? [PDF]

Global Journal on Quality and Safety in Healthcare, 2020
Therapeutic drug monitoring (TDM) has as its main objective to ensure that the plasma drug concentration remains within the appropriate range. Regarding the economic dimension of TDM, it is known that there are gains in health outcomes; however, there is
Pedro Cardoso, C. Santos, Francisco Rocha-Gonçalves   +2 more
doaj   +1 more source

Survival Outcomes and Complications Among Canadian Children With Retinoblastoma: A Population‐Based Report From CYP‐C

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Purpose Retinoblastoma (RB) is the most common pediatric ocular cancer, yet population‐based data on survival and risk factors remain limited. This study aimed to describe survival in a large national RB cohort and identify predictors of death and complications.
Samuel Sassine, Ofélie Trudeau‐Ferrin, Caroline Laverdière, Patrick Hamel, Rosanne Superstein, Bénédicte Koukoui, Carole Provost, Paul C. Nathan, Vijay Ramaswamy, Furqan Shaikh, Brenda Gallie, Ashwin Mallipatna, Stephanie Kletke, Helen Dimaras, Hallie Coltin   +14 more
wiley   +1 more source

Referral Burden and Cost of Outpatient Care of Patients Covered by the Rural Insurance Fund before and after the Implementation of Electronic Referral System in Golestan Province

Rāhburdhā-yi Mudīriyyat dar Niẓām-i Salāmat, 2021
Background: Part of the major health costs is related to outpatient care. Since the costs of diagnosis and treatment are increasing rapidly and increasingly, this study was conducted to determine the referral burden and cost of outpatient care of ...
Anis Abbasi, Mohammad Javad Kabir, Fatemeh Kavian Telouri, Alireza Heidari, Zahra Khatirnamani, Narges Rafiei, Anahita Keshavarzi   +6 more
doaj  

What's Good for Washington: Fair Prescription Drug Pricing and the Biotechnology Industry [PDF]

, 2003
The rising cost of prescription drugs is consuming an ever-larger portion of limited funds for basic health care and other important services in Washington state.
Rebecca Kavoussi
core  

City-wide Analysis of Electronic Health Records Reveals Gender and Age Biases in the Administration of Known Drug-Drug Interactions

, 2020
The occurrence of drug-drug-interactions (DDI) from multiple drug dispensations is a serious problem, both for individuals and health-care systems, since patients with complications due to DDI are likely to reenter the system at a costlier level.
Correia, Rion Brattig, de Araújo, Luciana P., Mattos, Mauro M., Rocha, Luis M.   +3 more
core   +1 more source